TG Therapeutics Inc (TGTX)
Receivables turnover
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Revenue | US$ in thousands | 324,397 | 221,047 | 2,785 | 6,689 | 152 |
| Receivables | US$ in thousands | 129,185 | 51,093 | 0 | 1,389 | — |
| Receivables turnover | 2.51 | 4.33 | — | 4.82 | — |
December 31, 2024 calculation
Receivables turnover = Revenue ÷ Receivables
= $324,397K ÷ $129,185K
= 2.51
The receivables turnover ratio for TG Therapeutics Inc has shown some fluctuations over the years, indicating changes in the company's ability to collect outstanding receivables.
In 2021, the receivables turnover ratio was 4.82, suggesting that the company collected its outstanding receivables approximately 4.82 times during the year. This high ratio indicates a relatively efficient collection process, which could be a positive sign for the company's cash flow and liquidity.
However, in 2024, the receivables turnover ratio decreased significantly to 2.51, indicating that the company's ability to collect outstanding receivables had decreased. A lower turnover ratio may suggest potential issues with customers' payment behaviors or credit policies, which could ultimately impact the company's cash flow and financial performance.
It is important for TG Therapeutics Inc to monitor its receivables turnover ratio consistently and take necessary actions to improve collections efficiency, such as implementing stricter credit policies or working closely with customers to expedite payments.
Peer comparison
Dec 31, 2024